Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Modulation of cellular membrane properties as a potential therapeutic strategy to counter lipointoxication in obstructive pulmonary diseases.

Kadri L, Ferru-Clément R, Bacle A, Payet LA, Cantereau A, Hélye R, Becq F, Jayle C, Vandebrouck C, Ferreira T.

Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):3069-3084. doi: 10.1016/j.bbadis.2018.06.021. Epub 2018 Jun 28.

PMID:
29960042
2.

In cellulo analyses of the p.Val322Ala mutation on the CFTR protein conformation and activity.

Farhat R, El-Seedy A, Sari AIP, Norez C, Pasquet MC, Becq F, Kitzis A, Ladevèze V.

C R Biol. 2017 Aug;340(8):367-371. doi: 10.1016/j.crvi.2017.06.001. Epub 2017 Aug 4.

3.

Development of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function.

Billet A, Froux L, Hanrahan JW, Becq F.

Front Pharmacol. 2017 Apr 7;8:195. doi: 10.3389/fphar.2017.00195. eCollection 2017.

4.

Calumenin contributes to ER-Ca2+ homeostasis in bronchial epithelial cells expressing WT and F508del mutated CFTR and to F508del-CFTR retention.

Philippe R, Antigny F, Buscaglia P, Norez C, Huguet F, Castelbou C, Trouvé P, Becq F, Frieden M, Férec C, Mignen O.

Cell Calcium. 2017 Mar;62:47-59. doi: 10.1016/j.ceca.2017.01.011. Epub 2017 Feb 4.

PMID:
28189267
5.

The Pig: A Relevant Model for Evaluating the Neutrophil Serine Protease Activities during Acute Pseudomonas aeruginosa Lung Infection.

Chevaleyre C, Riou M, Bréa D, Vandebrouck C, Barc C, Pezant J, Melo S, Olivier M, Delaunay R, Boulesteix O, Berthon P, Rossignol C, Burlaud Gaillard J, Becq F, Gauthier F, Si-Tahar M, Meurens F, Berri M, Caballero-Posadas I, Attucci S.

PLoS One. 2016 Dec 16;11(12):e0168577. doi: 10.1371/journal.pone.0168577. eCollection 2016.

6.

Myelinosomes act as natural secretory organelles in Sertoli cells to prevent accumulation of aggregate-prone mutant Huntingtin and CFTR.

Yefimova MG, Béré E, Cantereau-Becq A, Harnois T, Meunier AC, Messaddeq N, Becq F, Trottier Y, Bourmeyster N.

Hum Mol Genet. 2016 Oct 1;25(19):4170-4185. doi: 10.1093/hmg/ddw251. Epub 2016 Aug 4.

PMID:
27493027
7.

Targeting surface voids to counter membrane disorders in lipointoxication-related diseases.

Ferru-Clément R, Spanova M, Dhayal S, Morgan NG, Hélye R, Becq F, Hirose H, Antonny B, Vamparys L, Fuchs PF, Ferreira T.

J Cell Sci. 2016 Jun 15;129(12):2368-81. doi: 10.1242/jcs.183590. Epub 2016 May 3.

8.

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G.

J Innate Immun. 2016;8(4):330-49. doi: 10.1159/000444256. Epub 2016 Mar 18. Review.

9.

Pushing the limits of catalytic C-H amination in polyoxygenated cyclobutanes.

Nocquet PA, Hensienne R, Wencel-Delord J, Laigre E, Sidelarbi K, Becq F, Norez C, Hazelard D, Compain P.

Org Biomol Chem. 2016 Mar 7;14(9):2780-96. doi: 10.1039/c5ob02602d.

PMID:
26860404
10.

Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.

Cendret V, Legigan T, Mingot A, Thibaudeau S, Adachi I, Forcella M, Parenti P, Bertrand J, Becq F, Norez C, Désiré J, Kato A, Blériot Y.

Org Biomol Chem. 2015 Nov 21;13(43):10734-44. doi: 10.1039/c5ob01526j.

PMID:
26356422
11.

A functional tandem between transient receptor potential canonical channels 6 and calcium-dependent chloride channels in human epithelial cells.

Bertrand J, Dannhoffer L, Antigny F, Vachel L, Jayle C, Vandebrouck C, Becq F, Norez C.

Eur J Pharmacol. 2015 Oct 15;765:337-45. doi: 10.1016/j.ejphar.2015.08.005. Epub 2015 Aug 8.

PMID:
26265544
12.

Predicting CFTR activity with front-runner cystic fibrosis drugs.

Becq F.

EBioMedicine. 2015 Jan 27;2(2):100-1. doi: 10.1016/j.ebiom.2015.01.013. eCollection 2015 Feb. No abstract available.

13.

Vasorelaxation induced by dodoneine is mediated by calcium channels blockade and carbonic anhydrase inhibition on vascular smooth muscle cells.

Carre G, Ouedraogo M, Magaud C, Carreyre H, Becq F, Bois P, Supuran CT, Thibaudeau S, Vandebrouck C, Bescond J.

J Ethnopharmacol. 2015 Jul 1;169:8-17. doi: 10.1016/j.jep.2015.03.037. Epub 2015 Apr 3.

PMID:
25847623
14.

Involvement of the Cdc42 pathway in CFTR post-translational turnover and in its plasma membrane stability in airway epithelial cells.

Ferru-Clément R, Fresquet F, Norez C, Métayé T, Becq F, Kitzis A, Thoreau V.

PLoS One. 2015 Mar 13;10(3):e0118943. doi: 10.1371/journal.pone.0118943. eCollection 2015.

15.

SERCA and PMCA pumps contribute to the deregulation of Ca2+ homeostasis in human CF epithelial cells.

Philippe R, Antigny F, Buscaglia P, Norez C, Becq F, Frieden M, Mignen O.

Biochim Biophys Acta. 2015 May;1853(5):892-903. doi: 10.1016/j.bbamcr.2015.01.010. Epub 2015 Feb 4.

16.

The low PLC-δ1 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity.

Vachel L, Norez C, Jayle C, Becq F, Vandebrouck C.

Cell Calcium. 2015 Jan;57(1):38-48. doi: 10.1016/j.ceca.2014.11.005. Epub 2014 Nov 18.

PMID:
25477137
17.

N- and C-alkylation of seven-membered iminosugars generates potent glucocerebrosidase inhibitors and F508del-CFTR correctors.

Désiré J, Mondon M, Fontelle N, Nakagawa S, Hirokami Y, Adachi I, Iwaki R, Fleet GW, Alonzi DS, Twigg G, Butters TD, Bertrand J, Cendret V, Becq F, Norez C, Marrot J, Kato A, Blériot Y.

Org Biomol Chem. 2014 Nov 28;12(44):8977-96. doi: 10.1039/c4ob00325j.

PMID:
25277226
18.

Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Norez C, Vandebrouck C, Bertrand J, Noel S, Durieu E, Oumata N, Galons H, Antigny F, Chatelier A, Bois P, Meijer L, Becq F.

Br J Pharmacol. 2014 Nov;171(21):4831-49. doi: 10.1111/bph.12859.

19.

Function, pharmacological correction and maturation of new Indian CFTR gene mutations.

Sharma H, Jollivet Souchet M, Callebaut I, Prasad R, Becq F.

J Cyst Fibros. 2015 Jan;14(1):34-41. doi: 10.1016/j.jcf.2014.06.008. Epub 2014 Jul 16.

20.

A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.

Boucherle B, Bertrand J, Maurin B, Renard BL, Fortuné A, Tremblier B, Becq F, Norez C, Décout JL.

Eur J Med Chem. 2014 Aug 18;83:455-65. doi: 10.1016/j.ejmech.2014.06.028. Epub 2014 Jun 14.

PMID:
24992073
21.

Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.

Boinot C, Jollivet Souchet M, Ferru-Clément R, Becq F.

J Pharmacol Exp Ther. 2014 Sep;350(3):624-34. doi: 10.1124/jpet.114.214890. Epub 2014 Jun 26.

22.

Cystic fibrosis bronchial epithelial cells are lipointoxicated by membrane palmitate accumulation.

Payet LA, Kadri L, Giraud S, Norez C, Berjeaud JM, Jayle C, Mirval S, Becq F, Vandebrouck C, Ferreira T.

PLoS One. 2014 Feb 19;9(2):e89044. doi: 10.1371/journal.pone.0089044. eCollection 2014.

23.

Improvement of chloride transport defect by gonadotropin-releasing hormone (GnRH) in cystic fibrosis epithelial cells.

Benz N, Le Hir S, Norez C, Kerbiriou M, Calvez ML, Becq F, Trouvé P, Férec C.

PLoS One. 2014 Feb 19;9(2):e88964. doi: 10.1371/journal.pone.0088964. eCollection 2014.

24.

The hypotensive agent dodoneine inhibits L-type Ca2+ current with negative inotropic effect on rat heart.

Carré G, Carreyre H, Ouedraogo M, Becq F, Bois P, Thibaudeau S, Vandebrouck C, Bescond J.

Eur J Pharmacol. 2014 Apr 5;728:119-27. doi: 10.1016/j.ejphar.2014.01.059. Epub 2014 Feb 5.

PMID:
24508520
25.

ANO1 contributes to angiotensin-II-activated Ca2+-dependent Cl- current in human atrial fibroblasts.

El Chemaly A, Norez C, Magaud C, Bescond J, Chatelier A, Fares N, Findlay I, Jayle C, Becq F, Faivre JF, Bois P.

J Mol Cell Cardiol. 2014 Mar;68:12-9. doi: 10.1016/j.yjmcc.2013.12.027. Epub 2014 Jan 9.

PMID:
24412532
26.

The human CFTR protein expressed in CHO cells activates aquaporin-3 in a cAMP-dependent pathway: study by digital holographic microscopy.

Jourdain P, Becq F, Lengacher S, Boinot C, Magistretti PJ, Marquet P.

J Cell Sci. 2014 Feb 1;127(Pt 3):546-56. doi: 10.1242/jcs.133629. Epub 2013 Dec 11.

27.

Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors.

Compain P, Decroocq C, Joosten A, de Sousa J, Rodríguez-Lucena D, Butters TD, Bertrand J, Clément R, Boinot C, Becq F, Norez C.

Chembiochem. 2013 Oct 11;14(15):2050-8. doi: 10.1002/cbic.201300312. Epub 2013 Sep 13.

PMID:
24038832
28.

Saturated fatty acids alter the late secretory pathway by modulating membrane properties.

Payet LA, Pineau L, Snyder EC, Colas J, Moussa A, Vannier B, Bigay J, Clarhaut J, Becq F, Berjeaud JM, Vandebrouck C, Ferreira T.

Traffic. 2013 Dec;14(12):1228-41. doi: 10.1111/tra.12117. Epub 2013 Oct 2.

29.

Strategies to circumvent the CFTR defect in cystic fibrosis.

Becq F, Chanson M.

Front Pharmacol. 2013 Aug 29;4:108. doi: 10.3389/fphar.2013.00108. eCollection 2013. No abstract available.

30.

Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.

Odolczyk N, Fritsch J, Norez C, Servel N, da Cunha MF, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K, Tondelier D, Roldan A, Saussereau EL, Melin-Heschel P, Wieczorek G, Lukacs GL, Dadlez M, Faure G, Herrmann H, Ollero M, Becq F, Zielenkiewicz P, Edelman A.

EMBO Mol Med. 2013 Oct;5(10):1484-501. doi: 10.1002/emmm.201302699. Epub 2013 Aug 27.

31.

Bronchorelaxation of the human bronchi by CFTR activators.

Norez C, Jayle C, Becq F, Vandebrouck C.

Pulm Pharmacol Ther. 2014 Feb;27(1):38-43. doi: 10.1016/j.pupt.2013.06.008. Epub 2013 Jul 1.

PMID:
23827485
32.

Effect of VX-770 (ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells.

Vachel L, Norez C, Becq F, Vandebrouck C.

J Cyst Fibros. 2013 Dec;12(6):584-91. doi: 10.1016/j.jcf.2013.05.008. Epub 2013 Jun 10.

33.

C-branched iminosugars: α-glucosidase inhibition by enantiomers of isoDMDP, isoDGDP, and isoDAB-L-isoDMDP compared to miglitol and miglustat.

Jenkinson SF, Best D, Saville AW, Mui J, Martínez RF, Nakagawa S, Kunimatsu T, Alonzi DS, Butters TD, Norez C, Becq F, Blériot Y, Wilson FX, Weymouth-Wilson AC, Kato A, Fleet GW.

J Org Chem. 2013 Aug 2;78(15):7380-97. doi: 10.1021/jo4005487. Epub 2013 Jun 5.

PMID:
23688199
34.

Missense mutations in SLC26A8, encoding a sperm-specific activator of CFTR, are associated with human asthenozoospermia.

Dirami T, Rode B, Jollivet M, Da Silva N, Escalier D, Gaitch N, Norez C, Tuffery P, Wolf JP, Becq F, Ray PF, Dulioust E, Gacon G, Bienvenu T, Touré A.

Am J Hum Genet. 2013 May 2;92(5):760-6. doi: 10.1016/j.ajhg.2013.03.016. Epub 2013 Apr 11.

35.

CFTR: effect of ICL2 and ICL4 amino acids in close spatial proximity on the current properties of the channel.

Billet A, Mornon JP, Jollivet M, Lehn P, Callebaut I, Becq F.

J Cyst Fibros. 2013 Dec;12(6):737-45. doi: 10.1016/j.jcf.2013.02.002. Epub 2013 Mar 9.

36.

CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes.

El-Seedy A, Girodon E, Norez C, Pajaud J, Pasquet MC, de Becdelièvre A, Bienvenu T, des Georges M, Cabet F, Lalau G, Bieth E, Blayau M, Becq F, Kitzis A, Fanen P, Ladeveze V.

Hum Mutat. 2012 Nov;33(11):1557-65. doi: 10.1002/humu.22129. Epub 2012 Jul 2.

PMID:
22678879
37.

Deficit of osteoprotegerin release by osteoblasts from a patient with cystic fibrosis.

Gimenez-Maitre A, Le Henaff C, Norez C, Guillaume C, Ravoninjatovo B, Laurent-Maquin D, Becq F, Jacquot J.

Eur Respir J. 2012 Mar;39(3):780-1. doi: 10.1183/09031936.00104111. No abstract available.

38.

The testis anion transporter TAT1 (SLC26A8) physically and functionally interacts with the cystic fibrosis transmembrane conductance regulator channel: a potential role during sperm capacitation.

Rode B, Dirami T, Bakouh N, Rizk-Rabin M, Norez C, Lhuillier P, Lorès P, Jollivet M, Melin P, Zvetkova I, Bienvenu T, Becq F, Planelles G, Edelman A, Gacon G, Touré A.

Hum Mol Genet. 2012 Mar 15;21(6):1287-98. doi: 10.1093/hmg/ddr558. Epub 2011 Nov 25.

PMID:
22121115
39.

CFTR and Ca Signaling in Cystic Fibrosis.

Antigny F, Norez C, Becq F, Vandebrouck C.

Front Pharmacol. 2011 Oct 25;2:67. doi: 10.3389/fphar.2011.00067. eCollection 2011.

40.

Stimulation of Wild-Type, F508del- and G551D-CFTR Chloride Channels by Non-Toxic Modified pyrrolo[2,3-b]pyrazine Derivatives.

Dannhoffer L, Billet A, Jollivet M, Melin-Heschel P, Faveau C, Becq F.

Front Pharmacol. 2011 Aug 23;2:48. doi: 10.3389/fphar.2011.00048. eCollection 2011.

41.

Orphan missense mutations in the cystic fibrosis transmembrane conductance regulator: A three-step biological approach to establishing a correlation between genotype and phenotype.

Fresquet F, Clement R, Norez C, Sterlin A, Melin P, Becq F, Kitzis A, Thoreau V, Bilan F.

J Mol Diagn. 2011 Sep;13(5):520-7. doi: 10.1016/j.jmoldx.2011.05.004. Epub 2011 Jun 25.

42.

Effects of CFTR gene silencing by siRNA or the luminal application of a CFTR activator on fluid secretion from guinea-pig pancreatic duct cells.

Ko SB, Yamamoto A, Azuma S, Song H, Kamimura K, Nakakuki M, Gray MA, Becq F, Ishiguro H, Goto H.

Biochem Biophys Res Commun. 2011 Jul 15;410(4):904-9. doi: 10.1016/j.bbrc.2011.06.093. Epub 2011 Jun 17.

PMID:
21708133
43.

Pharmacological therapy for cystic fibrosis: from bench to bedside.

Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O.

J Cyst Fibros. 2011 Jun;10 Suppl 2:S129-45. doi: 10.1016/S1569-1993(11)60018-0. Review.

44.

Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain.

Ardes-Guisot N, Alonzi DS, Reinkensmeier G, Butters TD, Norez C, Becq F, Shimada Y, Nakagawa S, Kato A, Blériot Y, Sollogoub M, Vauzeilles B.

Org Biomol Chem. 2011 Aug 7;9(15):5373-88. doi: 10.1039/c1ob05119a. Epub 2011 Apr 21.

PMID:
21512716
45.

An expeditious access to 5-pyrimidinol derivatives from cyclic methylglyoxal diadducts, formation of argpyrimidines under physiological conditions and discovery of new CFTR inhibitors.

Renard BL, Boucherle B, Maurin B, Molina MC, Norez C, Becq F, Décout JL.

Eur J Med Chem. 2011 May;46(5):1935-41. doi: 10.1016/j.ejmech.2011.02.037. Epub 2011 Feb 23.

PMID:
21397997
46.

4-C-Me-DAB and 4-C-Me-LAB - enantiomeric alkyl-branched pyrrolidine iminosugars - are specific and potent α-glucosidase inhibitors; acetone as the sole protecting group.

da Cruz FP, Newberry S, Jenkinson SF, Wormald MR, Butters TD, Alonzi DS, Nakagawa S, Becq F, Norez C, Nash RJ, Kato A, Fleet GW.

Tetrahedron Lett. 2011 Jan 12;52(2):219-223.

47.

CFTR channels and adenosine triphosphate release: the impossible rendez-vous revisited in skeletal muscle.

Becq F.

J Physiol. 2010 Dec 1;588(Pt 23):4605-6. doi: 10.1113/jphysiol.2010.200113. No abstract available.

48.

From the vasodilator and hypotensive effects of an extract fraction from Agelanthus dodoneifolius (DC) Danser (Loranthaceae) to the active compound dodoneine.

Ouedraogo M, Ruiz M, Vardelle E, Carreyre H, Coustard JM, Potreau D, Sawadogo LL, Cognard C, Becq F, Vandebrouck C, Bescond J.

J Ethnopharmacol. 2011 Jan 27;133(2):345-52. doi: 10.1016/j.jep.2010.10.002. Epub 2010 Oct 16.

PMID:
20937377
49.

Understanding nucleotide binding and CFTR ion channel gating: how many cycles?

Becq F, Billet A.

Expert Rev Respir Med. 2010 Aug;4(4):451-4. doi: 10.1586/ers.10.47. No abstract available.

PMID:
20658906
50.

C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation.

Billet A, Melin P, Jollivet M, Mornon JP, Callebaut I, Becq F.

J Biol Chem. 2010 Jul 16;285(29):22132-40. doi: 10.1074/jbc.M110.120683. Epub 2010 Apr 30.

Supplemental Content

Support Center